Toxicity Signals Associated with Secukinumab: A Pharmacovigilance Study Based on The United States Food And Drug Administration Adverse Event Reporting System Database
Br J Clin Pharmacol. 2022 doi: 10.1111/bcp.15535
This study explored the clinical characteristics, outcomes, and time to onset of the four main toxicities of secukinumab with hypersensitivity identified as the most common toxicity.
Tofacitinib e Farmaci Antireumatici Sintetici Convenzionali Modificanti l’Attività di Malattia in Pazienti Cinesi con Artrite Reumatoide: Esiti Rilevati dai Pazienti da un Trial Controllato, Randomizzato, di Fase 3
Int J Rheum Dis 2018; 21(2):402–14This Chinese sub-population of patients with RA from ORAL Sync reported significant improvements in patient-reported outcomes (PROs), which were maintained up to 12 months from tofacitinib (TOF) treatment initiation. ORAL Sync was a randomised, Phase 3 study investigating TOF therapy in combination with csDMARDs in patients with active RA who had previously had an inadequate response to csDMARDs. To date, this is the only Phase 3 study of TOF in patients from China with RA. This analysis include...